With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt

Bristol Myers Squibb has agreed to pay $80 million for exclusive rights to an experimental drug for Alzheimer's disease developed by Prothena, a biotechnology company whose research focuses on dysfunctional proteins.